Levonantradol is a synthetic cannabinoid analogue of delta (9)-tetrahydrocannabinol (delta(9)-THC) administered intramuscularly. It has antiemetic and anti-analgesic properties. Although its precise mechanism of action is unknown, levonantradol appears to bind and activate the cannabinoid receptors CB1 and/or CB2. Antiemetic effect of levonantradol significantly superior to chlorpromazine. However, its adverse central effects limit its utility. The main adverse events are drowsiness and dizziness. Levonantradol, administered intramuscularly to the patients suffering from postoperative pain, manifested significant analgesic efficacy. Analgesia persisted for more than 6 h with the 2.5 and 3 mg doses of levonantradol. Drowsiness was frequent but few other psychoactive effects were reported.

ISOMETAMIDIUM (as a chloride salt) is widely used in tropical countries as an antiprotozoal agent to control animal trypanosomiasis. It is used principally in cattle but also in sheep, goats, buffalos, donkeys, horses, camels and dogs.

Atocalcitol is a vitamin D analogue. A hallmark of vitamin D3 analogues in psoriasis amelioration is the ability to inhibit the proliferation of keratinocytes. Atocalcitol had been in phase II clinical trials for the treatment of psoriasis. However, this research has been discontinued.

Terestigmine (also known as CHF-2060), a cholinesterase inhibitor, was developed for the treatment of cognition disorders in Italy. However, this study was discontinued.

Elziverine (RO 224839, ebiverine) is a cerebral and peripheral vasodilator. Elziverine was being developed for the treatment of cognition and neurological disorders.

Enazadrem (CP-70490-09) is an antipsoriatic agent inhibiting arachidonate 5-lipoxygenase.

Brosotamide is organic compound useful as sedative, muscle-relaxing, antipyretic, choleretic, and analgesic agents